Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

Selling, General, and Administrative Expenses (SG&A) [USD, Millions]

Research and Development (R&D) [USD, Millions]

Depreciation and Amortization (D&A) [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

Earnings Per Share (EPS) - Basic [USD]

Earnings Per Share (EPS) - Diluted [USD]

cfe0eefd133e8a7d9c5d3777f9ee7c20bdb21db56057370531179ac31c0f28b1

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from Debt [USD, Millions]

Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

9d1b0c1af8367b8166d03dbbff96cd76de6c4f8a13c77519d1254dcdd170c80b

United States

International

- Emerging Markets

EMEA (Europe, Middle East, Africa)

Greater Asia

Other (Latin America and Canada)

Total Revenue

7537be7aa194553082f2f57dffb73a1962ccaef3c89e51c2a96b41f2834b9171

ec1bb7e9b9f321321b2f55014201155eabce50e976b7ffa0033eb0d7341a8090

c4f74fd524d33e1bb7137f711b2ddc043f7334d72e3e456e23bc54dd63d02ab3

6d2bcd263d04b239967b53ae682d5ab27655278ecf1a92d403663c826e7d84d8

Cash and equivalents (USD, millions)

Restricted cash (USD, millions)

Short-term investments (USD, millions)

Trade receivables, net (USD, millions)

Inventories: Materials (USD, millions)

Inventories: Work in process (USD, millions)

Inventories: Finished products (USD, millions)

Inventories (USD, millions)

Prepaid expenses and other (USD, millions)

Total Current Assets (USD, millions)

Property, Plant and Equipment (USD, millions)

Less allowances for depreciation and amortization (USD, millions)

Property, Plant and Equipment, Net (USD, millions)

Goodwill (USD, millions)

Developed Technology, Net (USD, millions)

Customer Relationships, Net (USD, millions)

Other Intangibles, Net (USD, millions)

Other Assets (USD, millions)

Total Assets (USD, millions)

Current debt obligations (USD, millions)

Payables, accrued expenses and other current liabilities (USD, millions)

Total Current Liabilities (USD, millions)

Long-Term Debt (USD, millions)

Long-Term Employee Benefit Obligations (USD, millions)

Deferred Income Taxes and Other Liabilities (USD, millions)

Common stock (USD, millions)

Capital in excess of par value (USD, millions)

Retained earnings (USD, millions)

Deferred compensation (USD, millions)

Treasury stock (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total Shareholders’ Equity (USD, millions)

Total Liabilities and Shareholders’ Equity (USD, millions)

eeb12d02a7357dc2df773255d8e4cd05bb86281db087ceac4c5f52dbf551d668

The spike in Cash and Cash Equivalents in Q3 2024 was primarily driven by **significant proceeds from long-term debt issuance** (amounting to **$4,517 million**) and **strong operating cash flows** (with **$2,666 million** generated from continuing operations), which were further bolstered by additional liquidity from the **factoring of trade receivables** (worth **$1,115 million**). These factors outweighed the cash used for investing and financing activities, leading to the overall increase in cash levels.  **[0000010795-24-000067_bdx-20240630.htm:21]** **[20240801NY74029:15]** **[0000010795-24-000064_ex99106302024.htm:10]** 

Why did Cash and Cash Equivalents spike in Q3 2024?

The **total assets** reached **$57,286 million** in Q4 2024 due to several factors, including an **increase in goodwill** from **$24,522 million** in 2023 to **$26,465 million** in 2024, higher **trade receivables** (rising from **$2,534 million** to **$3,033 million**), increased **inventories** (from **$3,273 million** to **$3,843 million**), improved **cash and equivalents** (from **$1,416 million** to **$1,717 million**), and a significant rise in **short-term investments** (from **$8 million** to **$445 million**). These changes collectively contributed to the overall increase in total assets in Q4 2024.  **[20241107NY49057:0]** **[0000010795-24-000084_bdx-20240930.htm:95]** 

Why did Total Assets reach 57,286 in Q4 2024?

The increase in long-term debt in Q3 2024 was primarily driven by **proceeds from long-term debt issuance of $4,517 million** and was partially offset by **debt payments of $1,142 million**. Additionally, the company undertook strategic financing for the **$4.2 billion acquisition of Edwards Lifesciences' Critical Care Product Group**, which further contributed to the rise in debt.  **[0000010795-24-000067_bdx-20240630.htm:3]** **[0000010795-24-000064_ex99106302024.htm:0]** **[20240801NY74029:0]** 

What caused the increase in Long-Term Debt in Q3 2024?

The documents show that Becton, Dickinson and Company reported **$2,016 million** in current debt obligations for Q2 2024  **[0000010795-24-000039_bdx-20240331.htm:3]**  and **$1,192 million** for Q3 2024.  **[0000010795-24-000067_bdx-20240630.htm:3]**  Although this represents a significant drop, the documents do not provide specific reasons for the decline. It is possible that the reduction resulted from routine debt management activities such as repayments or refinancing, but no definitive explanation is provided in the available information.  **[0000010795-24-000067_bdx-20240630.htm:3]** 

Why did Current Debt Obligations drop in Q3 2024?

ca30c746b700d50318299a28a0ee6164ec1d6e8b45fade975a36ce03cfe00758

Becton Dickinson and Co (BDX)

Financials